Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 96
- 试验地点
- 2
- 主要终点
- expression levels of p53/L1CAM/ER/PR
研究概览
简要总结
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment.
Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 36 Years 至 72 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •aged 36 -72 years;
- •Previously diagnosed with endometrial carcinoma;
- •Histological Type of the tumor;
- •Myometrial Invasion;
- •lymph Node Invasion;
- •Cervical Invasion;
- •Biomarkers expression.
排除标准
- •Lack of tumor tissue in tissue block
结局指标
主要结局
expression levels of p53/L1CAM/ER/PR
时间窗: 36 Months
The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups
次要结局
未报告次要终点
研究者
Walid Mohamed Elnagar
Assistant professor of gynecology
Zagazig University